Health

Johnson & Johnson To Start Single-shot Vaccine Trials in India

US pharma giant Johnson & Johnson is reportedly in talks with the Indian government to begin a clinical trial of its single-shot COVID-19 vaccine. This news comes at a critical juncture in India’s fight against a rising tide of COVID cases nationwide.

Johnson & Johnson met with the Drugs Controller General of India (DCGI) to get approval for holding clinical trials in the country. The one-shot COVID vaccine developed by the healthcare company is currently adopted in the United States, the European Union and others including South Africa and Thailand.

A spokesperson for the Indian department of the company said, “We are in discussions with the Government of India with the objective of starting a bridging clinical study of our Janssen COVID-19 vaccine candidate in India, subject to local regulatory approvals.”

The DCGI has always stressed on the importance of bridging studies and had even refused Pfizer import licence for its messenger RNA vaccine.

Johnson & Johnson has also roped in Hyderabad-based Biological E as a manufacturer for its single-shot vaccines.

The vaccine could be a critical tool in India’s arsenal due to its proven track record in the US with a success rate of 66.3%.

The Indian government has currently approved two vaccines to be used for vaccination drives – the AstraZeneca-Oxford vaccine and a domestic variant from Bharat Biotech.

As several states in India are struggling to get their citizens vaccinated amidst growing concerns of vaccine shortage, the latest announcement by Johnson & Johnson should calm frayed nerves.

Top government sources confirmed the news in a statement saying, “Johnson & Johnson has sent a letter to the CDSCO (Central Drugs Standard Control Organisation) that they will very shortly apply for permission to conduct clinical bridging trials in India.”

A successful trial could see the vaccines being marketed in India which will relieve the burden on Serum Institute of India and Bharat Biotech, which are already struggling to increase production capacities.

Andrew s

Andrew has been in the online publishing industry. After receiving his degree in professional journalism from the Indian Institute of Journalism and New Media, he contributed to multiple websites as a freelance writer and feature editor. Mostly, Andrew tackles controversies and theories that lead to a specific conclusion that either debunk or justify a particular claim. Further, Andrew participates in social developments that aim to simplify every individual's way of life and fight for peace. He is the new Editor-in-Chief of Pressroom Today.

Share
Published by
Andrew s

Recent Posts

Bharat Club App Review | Play Games & Earn ₹500 In APK

Do you want to earn a side income? This time the side income trend is…

1 month ago

IPL 2024 Kicks Off In Style: All-Star Teams Prepare to Play for the Cup

The popular sports league, which garners significant viewership from India and abroad, has initiated its…

3 months ago

Lok Sabha Elections 2024: India’s Future Awaits ‘Saath Phase Paar’

The total number of registered voters is more than the combined population of all European…

3 months ago

Scam 2024: The Electoral Bonds Scheme And Its Top Contributors Come to Light

Who paid whom, how much and WHY? These are the general questions that everyone asked…

3 months ago

Centre Notifies Rules for CAA: Stirs the Indian Political Arena Across Different Levels

The new legislation aims to uplift persecuted minorities by granting them Indian citizenship based on…

3 months ago

Centre Notifies Rules for CAA: Stirs the Indian Political Arena Across Different Levels

The new legislation aims to uplift persecuted minorities by granting them Indian citizenship based on…

3 months ago